Nanobiotix announced two poster presentations at the 2025 European Lung Cancer Conference showcasing Phase 1 study data for JNJ-1900 (NBTXR3) in patients with non-small cell lung cancer (NSCLC). One study evaluated the safety and efficacy of re-irradiation with NBTXR3 in patients with unresectable, locoregional recurrent NSCLC. The other explored the safety and feasibility of injecting NBTXR3 in combination with nivolumab or pembrolizumab in patients with lung metastases originating from NSCLC or other solid tumors.
These presentations are important because they provide preliminary insights into the potential of NBTXR3 in expanding treatment options for lung cancer, a leading cause of cancer-related deaths worldwide. The studies explore the use of NBTXR3 in challenging clinical scenarios like recurrent and metastatic disease, where new therapies are critically needed. Positive data could significantly advance the development of NBTXR3 in lung cancer, potentially leading to improved outcomes for patients who have limited treatment choices.
The first presentation showcased updated local progression-free survival data from the completed dose-escalation portion of a Phase 1 re-irradiation study. The second highlighted safety and injection feasibility data from a Phase 1 study combining NBTXR3 with checkpoint inhibitors. Both studies are crucial stepping stones towards larger, more definitive clinical trials.
The data presented at ELCC represent a significant step in validating the potential of NBTXR3 in lung cancer. Positive findings could lead to accelerated development timelines, further clinical investigation, and ultimately, provide a new therapeutic approach for patients with this aggressive and often difficult-to-treat disease. Further investigation will be needed to confirm these early signals and determine the optimal use of NBTXR3 in different lung cancer settings.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
